You searched for "treatment"
Management of stage 1 non-seminomatous germ cell tumours
Testicular cancer (TC) is the most successfully treated solid tumour, achieving a cure rate of 90-95% [1-3]. Testicular cancer is relatively rare with an incidence of 2207 cases in the UK in 2014 [4] and yet is the most common...
Preoperative stenting compared to non‑stenting in ureteroscopy for urinary stone disease
Urolithiasis, one of the most prevalent urological conditions worldwide, significantly affects patients’ quality of life. In the United States, its lifetime prevalence is approximately 1 in 11, while global rates vary from 1% to 13%. The management of urolithiasis offers...Prostate cancer spit test could save the NHS £500 million a year
Thousands of men could have their prostate cancer diagnosed at an earlier stage when it is easier and cheaper to treat, thanks to a new spit test which can be taken at home. An innovative new study launched this week,...
Factors associated with post ureteroscopy urosepsis
The authors investigate which factors were most likely to increase the risk of postoperative urosepsis within 28 days of ureteroscopy (URS) and laser stone fragmentation by analysing the 34 of 562 patients who developed this complication. Stone size, same session...
Tissue-based biomarkers steering clinical decisions in patients with urothelial cancer
Biomarkers play an essential role in the diagnosis and treatment of urothelial cancer (UC), with PD-L1, FGFR, and MMR proteins being the most clinically established. These biomarkers, derived from histological specimens, guide therapeutic decisions for bladder cancer (BCa) and upper...Prostate cancer: Black men more likely to be diagnosed at later stages
Latest data shows Black men have higher rates of stage 3 or stage 4 prostate cancer diagnoses compared with white men. Black men diagnosed at a later stage in their 60s are 14% less likely to get NICE approved treatment...Recent developments in bladder cancer
There have been some exciting developments in bladder cancer over the last few years. Immunotherapy has prolonged survival in a proportion of patients with metastatic disease, with sustained efficacy in some. Advances in genetic analysis and molecular subtyping make personalised...
